Barth Claire, Naveau Louise, Touboul Emmanuel, Périé Sophie, Bamogho Edith, Haberer-Guillerm Sophie, Schlienger Michel, Lacau St Guily Jean, Huguet Florence
Departments of aRadiation Oncology bHead and Neck Surgery, Tenon Hospital, HUEP, UPMC, Paris VI University, Paris, France.
Anticancer Drugs. 2016 Apr;27(4):349-52. doi: 10.1097/CAD.0000000000000333.
The aim of this study was to evaluate the efficacy and tolerance of vinorelbine as a single agent in the treatment of recurrent/metastatic head and neck squamous cell carcinoma. Patients were treated with oral or intravenous vinorelbine according to the pluridisciplinary tumor board's decision. Efficacy and safety outcomes were analyzed retrospectively. Twenty-three patients were included in the study. Sixteen patients (69%) had received at least two previous lines of chemotherapy. The disease control rate was 19%. The median progression-free survival was 2.6 months and the median overall survival was 3.4 months. The rate of grade 3-4 side effects was low (13%). Only one patient discontinued treatment because of side effects. Vinorelbine seems to be a well-tolerated regimen in heavily pretreated patients. However, this regimen does not seem to be efficient enough to be recommended.
本研究的目的是评估长春瑞滨单药治疗复发/转移性头颈部鳞状细胞癌的疗效和耐受性。根据多学科肿瘤委员会的决定，患者接受口服或静脉注射长春瑞滨治疗。对疗效和安全性结果进行回顾性分析。23例患者纳入本研究。16例患者（69%）此前至少接受过两线化疗。疾病控制率为19%。中位无进展生存期为2.6个月，中位总生存期为3.4个月。3-4级副作用发生率较低（13%）。仅1例患者因副作用停药。长春瑞滨似乎是一种在接受过大量预处理患者中耐受性良好的方案。然而，该方案似乎效率不够高，不足以推荐使用。
